A detailed history of Trilogy Capital Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Trilogy Capital Inc. holds 1,347 shares of LLY stock, worth $1.09 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
1,347
Previous 1,296 3.94%
Holding current value
$1.09 Million
Previous $1.17 Million 1.71%
% of portfolio
0.06%
Previous 0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$772.14 - $960.02 $39,379 - $48,961
51 Added 3.94%
1,347 $1.19 Million
Q2 2024

Jul 22, 2024

BUY
$724.87 - $909.04 $652,383 - $818,136
900 Added 227.27%
1,296 $1.17 Million
Q1 2024

Apr 17, 2024

BUY
$592.2 - $792.28 $234,511 - $313,742
396 New
396 $308,000
Q4 2018

Jan 15, 2019

SELL
$105.9 - $118.64 $4,977 - $5,576
-47 Closed
0 $0
Q1 2018

May 24, 2018

BUY
$74.21 - $87.6 $3,487 - $4,117
47 New
47 $4,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $771B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Trilogy Capital Inc. Portfolio

Follow Trilogy Capital Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trilogy Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Trilogy Capital Inc. with notifications on news.